lowtierwaffle
Iron
- Joined
- Jan 24, 2026
- Posts
- 26
- Reputation
- 14
Matrixyl doesn't work.
Matrixyl is a peptide in a huge number of serums and gets cited constantly. The evidence is almost nothing.
There's one real study. Robinson 2005. 93 women, 12 weeks. All six authors worked at Procter & Gamble. It used 3 parts per million of the peptide. That's the entire clinical case for original Matrixyl.
Everything else is marketing. The "collagen +105%" numbers, the fibroblast data, the Synthe'6 trial — that's all Sederma's own unpublished brochure material. Retailers host it as PDFs and people link it like it's a paper.
The doses you see quoted aren't the peptide. Synthe'6 as sold is 0.025% actual peptide in glycerin and water (it's in patent US9149659). So a "2% Synthe'6" serum contains 0.0005% peptide. Five ppm. Matrixyl 3000 is the same trick. And those percentages aren't proven doses — they're the supplier's suggested use range.
Cagefuel: In cell culture, you need roughly 100–500 nM to make a fibroblast do anything. At 3 ppm topically, you'd only hit that if 100% of it crossed the skin barrier intact. Choi 2014 measured it and found barely any reaches the dermis, and what does get in breaks down fast. Real-world you're 100–1000x below the level that does anything in a dish
One actual warning: don't dermastamp it. Park 2017 found pal-KTTKS at the concentrations needling actually achieves pushes fibroblasts toward the scarring phenotype (CTGF and α-SMA up, myofibroblast conversion). The authors flagged it themselves. The only reason topical Matrixyl is harmless is that nothing gets through — needling removes that. Also don't stamp in any non-sterile serum, that's how people get facial granulomas.
tl;dr: one industry study at 3 ppm, the "2%" on the label is 99.9% glycerin, nothing reaches the dermis, no one has ever found more collagen in treated skin. Harmless, useless, overpriced. Buy Tretinoin.
Citations:
Matrixyl is a peptide in a huge number of serums and gets cited constantly. The evidence is almost nothing.
There's one real study. Robinson 2005. 93 women, 12 weeks. All six authors worked at Procter & Gamble. It used 3 parts per million of the peptide. That's the entire clinical case for original Matrixyl.
Everything else is marketing. The "collagen +105%" numbers, the fibroblast data, the Synthe'6 trial — that's all Sederma's own unpublished brochure material. Retailers host it as PDFs and people link it like it's a paper.
The doses you see quoted aren't the peptide. Synthe'6 as sold is 0.025% actual peptide in glycerin and water (it's in patent US9149659). So a "2% Synthe'6" serum contains 0.0005% peptide. Five ppm. Matrixyl 3000 is the same trick. And those percentages aren't proven doses — they're the supplier's suggested use range.
Cagefuel: In cell culture, you need roughly 100–500 nM to make a fibroblast do anything. At 3 ppm topically, you'd only hit that if 100% of it crossed the skin barrier intact. Choi 2014 measured it and found barely any reaches the dermis, and what does get in breaks down fast. Real-world you're 100–1000x below the level that does anything in a dish
One actual warning: don't dermastamp it. Park 2017 found pal-KTTKS at the concentrations needling actually achieves pushes fibroblasts toward the scarring phenotype (CTGF and α-SMA up, myofibroblast conversion). The authors flagged it themselves. The only reason topical Matrixyl is harmless is that nothing gets through — needling removes that. Also don't stamp in any non-sterile serum, that's how people get facial granulomas.
tl;dr: one industry study at 3 ppm, the "2%" on the label is 99.9% glycerin, nothing reaches the dermis, no one has ever found more collagen in treated skin. Harmless, useless, overpriced. Buy Tretinoin.
Citations:
- Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-4. PMID 8486721 — https://pubmed.ncbi.nlm.nih.gov/8486721/
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-60. PMID 18492182 — https://pubmed.ncbi.nlm.nih.gov/18492182/ · publisher: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1467-2494.2005.00261.x
- Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-7. PMID 25143811 — https://pubmed.ncbi.nlm.nih.gov/25143811/
- Abu Samah NH, Heard CM. Topically applied KTTKS: a review. Int J Cosmet Sci. 2011;33(6):483-90. PMID 21535443 — https://pubmed.ncbi.nlm.nih.gov/21535443/ · full text: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-2494.2011.00657.x
- Park H, An E, Cho Lee AR. Effect of palmitoyl-pentapeptide (Pal-KTTKS) on wound contractile process in relation with connective tissue growth factor and α-smooth muscle actin expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID 30603464 — https://pubmed.ncbi.nlm.nih.gov/30603464/ · free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC6171572/
- US Patent 9,149,659 — Cosmetic composition for increasing hyaluronic acid synthesis in skin and its use for repairing wrinkles. States Synthe'6 trade material composition: 0.025% palmitoyl tripeptide-38, 78.975% glycerin, 1.0% hydroxypropyl cyclodextrin, remainder water — https://patents.google.com/patent/US9149659B2/en
